Aquestive Therapeutics vs Journey Medical
Journey Medical is the larger business, with $61.9m of revenue in fiscal 2025 against $44.5m for Aquestive Therapeutics (1.4 times as much). Journey Medical grew faster (10.2% against -22.6%). Journey Medical kept more of each dollar of sales as profit: a net margin of -18.5% against -188.1%.
| Latest fiscal year | Aquestive TherapeuticsAQST, 2025 | Journey MedicalDERM, 2025 |
|---|---|---|
| Revenue | $44.5m | $61.9m |
| Revenue growth | -22.6% | 10.2% |
| Net income | −$83.8m | −$11.4m |
| Operating margin | -159.5% | -13.2% |
| Net margin | -188.1% | -18.5% |
| Return on equity | — | -44.0% |
| Free cash flow | −$53.0m | −$12.4m |
| Cash | $121m | $24.1m |
| Total debt | $55.0m | $26.3m |
| Debt to equity | — | 82.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 147 | 58 |
| Market value | $485m | $129m |
| Price vs our value range | — | — |
| Moat score | 24 (Weak) | 35 (Weak) |
| Insider trades, 12 months | 0 buys, 16 sales | 0 buys, 0 sales |